Targeted Oncology

XTR008 Demonstrates Survival and Response Superiority in SSTR+ GEP-NETs

XTR008 significantly improved PFS, ORR, and quality of life compared to octreotide LAR in SSTR-positive GEP-NETs. XTR008 therapy shows significant benefits in treating GEP-NETs, enhancing survival ...
ascopubs.org

Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on ...

A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract ...
Reuters

Novartis says Signifor LAR drug helps control acromegaly disease

ZURICH, May 5 (Reuters) - Swiss drugmaker Novartis said on Monday a final-stage trial of its Signifor LAR therapy allowed for greater disease control in patients with the endocrine disorder acromegaly ...
ascopubs.org

Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14

Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14 ...